Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Here are some recent analyst ratings: Guggenheim issued a "Buy" rating on 01/20/2026 B of A Securities issued a "Buy" rating on 12/15/2025 Wells Fargo issued a "Overweight" rating on 12/10/2025 BMO Capital issued a "Outperform" rating on 12/04/2025 Morgan Stanley issued a "Overweight" rating on 11/24/2025 Bernstein issued a "Outperform" rating on 11/24/2025 Truist Securities issued a "Buy" rating on 11/19/2025 To track analyst ratings and price targets for Eli Lilly, check out Quiver Quantitative's $LLY forecast page
3-indole-2-propynyl butylcarbamate
In two additional patients with prior disease progress, diazoxide treatment resulted in stable disease of 8 (combined with tamoxifen) and 4 months (monotherapy)
Its advisable to use them under the guidance of a healthcare professional, especially for long-term use
US$ 28.86
US$ 20.68
US$ 27.60
US$ 29.23
US$ 28.53
US$ 23.59
US$ 28.08
US$ 29.13
